Read more

March 24, 2022
1 min read
Save

Top in hem/onc: Social media for oncologists, rise in metastatic prostate cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Social media has become the primary communication mode of the 21st century, and many physicians have started incorporating it into their practices.

Specialists from the Collaboration for Outcomes using Social Media in Oncology spoke with Healio about the dos and don’ts of social media use among oncologists. It was the top story in hematology/oncology last week.

smartphone on table
Source: Adobe Stock

The second top story was about an increase in metastatic prostate cancer, and the possible association with the 2008 and 2012 changes in USPSTF recommendations against PSA-based prostate cancer screening.

Read these and more top stories in hematology/oncology below:

‘Like’ it or not: The dos and don’ts of social media for oncologists

Just as physicians became accustomed to wearing pagers 40 years ago or being tied to smartphones 2 decades ago, many have become active on social media as it entered their practices. Read more.

Rise in metastatic prostate cancer incidence coincides with screening guideline changes

Increases in metastatic prostate cancer incidence may be temporally associated with changes in clinical policy following U.S. Preventive Services Task Force recommendations, according to a study in JAMA Network Open. Read more.

New cancer diagnosis associated with risk for fatal, nonfatal cardiovascular events

New cancer diagnosis appeared to be associated with an increased risk for cardiovascular death, as well as incident heart failure, stroke or pulmonary embolism, according to a retrospective cohort study published in JACC: CardioOncology. Read more.

Only 14% of new cancer drug approvals displace existing standards of care

Most cancer drug approvals between 2016 and 2021 applied to second-, third- or later-line treatment settings and did not displace current standard-of-care therapies, according to a study published in JAMA Network Open. Read more.

ASH president advises that early-career women be persistent, ‘show up and be in the room’

Jane N. Winter, MD, the current American Society of Hematology president, said that it is essential to be persistent with your goals and choose mentors wisely during the early years of a medical career. Read more.